Presenting on the Emerging Growth Conference 68 Day 1 on March 6 Register Now
Sigyn Therapeutics Announces Reverse Stock Split
SAN DIEGO, CA, Jan. 30, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Sigyn Therapeutics, Inc. ("Sigyn" or the "Company") (OTCQB:SIGY), a development-stage medical technology company, today announced that a 1-for-40
Sigyn Therapeutics Announces Appointment of Jerry DeCiccio as Chief Financial Officer
SAN DIEGO, CA, Dec. 12, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Sigyn Therapeutics, Inc. ("Sigyn" or the "Company") (OTCQB:SIGY), a development-stage medical technology company, today announced the appointment of
Sigyn Therapeutics Inc GAAP EPS of -$0.02
Sigyn Therapeutics Reports Third Quarter 2023 Financial Results
SAN DIEGO, CA, Nov. 14, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire –Sigyn Therapeutics, Inc. ("Sigyn" or the "Company") (OTCQB:SIGY), a development-stage medical technology company, today announces financial results for
Sigyn Therapeutics Discloses PCT Patent Submission to Enhance Chemotherapy Delivery and Reduce Cancer Treatment Toxicity
SAN DIEGO, CA, Oct. 04, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Sigyn Therapeutics, Inc. ("Sigyn" or the "Company") (OTCQB:SIGY), a development-stage medical technology company, today disclosed the submission of a
Sigyn Therapeutics to Present at Today's Emerging Growth Conference and Tomorrow at the National Investment Bankers Association Conference
SAN DIEGO, CA, Sept. 06, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Sigyn Therapeutics, Inc. ("Sigyn" or the "Company") (OTCQB:SIGY), a medical technology company that creates blood purification therapies to address
Sigyn Therapeutics Reports Second Quarter 2023 Financial Results
SAN DIEGO, CA, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Sigyn Therapeutics, Inc. ("Sigyn" or the "Company") (OTCQB:SIGY), a medical technology company that creates blood purification devices to overcome clearly defined
Sigyn Therapeutics to Present at Tomorrow's Emerging Growth Conference
SAN DIEGO, CA, Aug. 08, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Sigyn Therapeutics, Inc. ("Sigyn" or the "Company") (OTCQB:SIGY), a medical technology company that creates blood purification devices to overcome
Sigyn Therapeutics to Present at the OTCQB Venture Virtual Investor Conference on August 3rd
SAN DIEGO, July 31, 2023 (GLOBE NEWSWIRE) -- Sigyn Therapeutics, Inc. ("Sigyn" or the "Company") (OTCQB:SIGY), a development-stage company that creates therapeutic blood purification candidates to overcome clearly
Sigyn Therapeutics Discloses "DEVICES FOR ENHANCING THE ACTIVITY OF THERAPEUTIC ANTIBODIES" Patent Submission and Related ImmunePrep Trademark Application
SAN DIEGO, CA, May 17, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Sigyn Therapeutics, Inc. ("Sigyn" or the "Company") (OTCQB:SIGY), a development-stage medical technology company, disclosed today that it has
Sigyn Therapeutics, Inc. GAAP EPS of -$0.03
Press Release: Sigyn Therapeutics Reports First Quarter 2023 Financial Results
Sigyn Therapeutics Reports First Quarter 2023 Financial Results SAN DIEGO, CA, May 16, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Sigyn Therapeutics, Inc. ("Sigyn" or the "Company") (OTCQB: SIGY),
Sigyn Therapeutics Announces Appointment of Annette Marleau, Ph.D. as Chief Scientific Officer
SAN DIEGO, CA, April 11, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Sigyn Therapeutics, Inc. (OTCQB:SIGY) ("Sigyn Therapeutics" or the "Company"), a development-stage company focused on the creation of blood
Sigyn Therapeutics Announces Filing of 2022 Annual Report on SEC Form 10-K
SAN DIEGO, CA, March 31, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Sigyn Therapeutics, Inc. (OTCQB: SIGY) ("Sigyn Therapeutics" or the "Company"), a development-stage company that creates blood pu
Press Release: Sigyn Therapeutics Announces Third Quarter 2022 Financial Results
Sigyn Therapeutics Announces Third Quarter 2022 Financial Results SAN DIEGO, CA, Nov. 15, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Sigyn Therapeutics, Inc. ("Sigyn" or the "Company") (OTCQB: SIGY
Sigyn Therapeutics™ Discloses Trademark Applications to Register ChemoPrep™ and ChemoPure™ for Devices to Enhance Cancer Therapy
SAN DIEGO, CA, Oct. 13, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Sigyn Therapeutics, Inc. ("Sigyn" or the "Company") (OTCQB: SIGY), a development-stage company focused on creating therapeutic sol
Sigyn Therapeutics™ Strengthens Board of Directors With the Appointments of Richa Nand, Jim Dorst and Christopher Wetzel
- Independent Directors Bring Expertise in Intellectual Property, Finance, Healthcare Delivery, and More - SAN DIEGO, CA, Oct. 04, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Sigyn Therapeutics, Inc
Sigyn Therapeutics Announces First-In-Human Clinical Strategy to Address Inflammation and Endotoxemia in End-Stage Renal Disease Patients
SAN DIEGO, CA, Sept. 14, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Sigyn Therapeutics, Inc. (OTCQB: SIGY), a development-stage company focused on the creation of therapeutic solutions that address
Sigyn Therapeutics, Inc. GAAP EPS of -$0.02
Sigyn Therapeutics, Inc. press release (OTCQB:SIGY): Q2 GAAP EPS of -$0.02. Second quarter 2022 net cash used in operating activities was approximately $395,000.
No Data